MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 2 Sell Rating(s), 4 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $9.28 (40.11% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetActions
5/17/2016FBR & Co.Reiterated RatingOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016BTIG ResearchReiterated RatingSell$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Maxim GroupReiterated RatingBuy$5.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$19.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Brean CapitalReiterated RatingBuy$18.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Stifel NicolausBoost Price TargetBuy$9.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Raymond JamesUpgradeMarket Perform -> Outperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$2.50 -> $1.80View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015MLV & Co.Reiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015MizuhoLower Price TargetBuy$25.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015OppenheimerLower Price TargetOutperform$22.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.38)($0.44)$1.39 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.27)($0.38)$0.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.25)($0.24)$0.28 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.08)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.21)($0.21)($0.21)
Q3 20161($0.19)($0.19)($0.19)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline
06/30/16 07:41 AM4 Swing Trades To Watch: AQMS, BCOR, KERX, MVDN
06/28/16 04:44 PMHC Stocks Reports: Minerva Neurosciences Inc (NASDAQ:NERV), Keryx Biopharmaceuticals (NASDAQ:KERX) - share market updates (press release)
06/28/16 09:43 AMStock Update (NASDAQ:KERX): Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and ... - Smarter Analyst
06/27/16 07:21 AMDouglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy - [at noodls] - BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced ...
06/24/16 04:48 PMStrong Sell Calls Recommendations For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 0 - Investor Newswire
06/24/16 04:48 PMPrice Target Update on Keryx Biopharmaceuticals (NASDAQ:KERX) - Trade Calls
06/24/16 07:27 AMKeryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Sellers Covered 1.36% of Their Shorts - Press Telegraph
06/24/16 07:27 AMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:22 AMKeryx Biopharmaceuticals Has Gained 19.8% So Far in 2016 -- Here's Why -
06/22/16 08:01 PMAmpliPhi Biosciences Corporation (NYSEMKT:APHB) Decreased -2.29%: Keryx Biopharmaceuticals Inc. (NASDAQ ... - KC Register
06/22/16 08:01 PMKeryx Biopharmaceuticals Inc. (NasdaqCM:KERX) Stock Momentum Hits Strength - CML News
06/22/16 08:01 PMKeryx Biopharmaceuticals (NASDAQ:KERX) Analyst Rating Consensus - TheFounders Daily
06/22/16 08:01 PMCompany Update (NASDAQ:KERX): Keryx Biopharmaceuticals Appoints Two New Board Members - Smarter Analyst
06/21/16 04:20 PMKERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
06/20/16 07:59 AMStrong Buy Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 6 - Investor Newswire
06/17/16 07:35 AMTake a look at Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , LDR Holding Corporation (NASDAQ ... - Street Updates
06/14/16 07:39 AMKeryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21 - [at noodls] - BOSTON, June 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced ...
06/13/16 07:39 AMHC Stocks Highlights: Keryx Biopharmaceuticals (NASDAQ:KERX), NuVasive, Inc. (NASDAQ:NUVA) - share market updates (press release)
06/11/16 07:37 AMEarnings Overview of the Stocks: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), The Valspar Corporation (NYSE:VAL) - Beacon Chronicle
06/07/16 04:59 PMHave a look at Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Vanda Pharmaceuticals Inc. (NASDAQ ... - Street Updates
06/06/16 04:43 PMHealthcare Laggards: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX ... - KC Register
06/06/16 08:33 AMUpdated Analysts Rating Report: Shire plc (SHPG) , Keryx Biopharmaceuticals, Inc. (KERX) - Street Updates
06/04/16 07:37 AMNotable Earnings Analysis: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Exelon Corporation (NYSE:EXC) - Beacon Chronicle
06/03/16 05:12 PMTwo Stocks within Analysts Review: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Keryx Biopharmaceuticals, Inc ... - Street Updates
06/03/16 07:34 AMHC Stocks Assessment: Keryx Biopharmaceuticals (NASDAQ:KERX), CytRx Corporation (NASDAQ:CYTR) - share market updates (press release) - HC Stocks Assessment: Keryx Biopharmaceuticals (NASDAQ:KERX), CytRx Corporation (NASDAQ:CYTR)share market updates (press release)Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) ended Thursday session in green amid volatile trading. The shares closed up +0.71 points or 11.87% at $6.69 with 4.48 million shares getting traded. Post opening the session at $6.30, the shares hit an ...
06/02/16 05:06 PMWorth Chasing Stocks: Cellectar Biosciences Inc (NASDAQ:CLRB), Keryx Biopharmaceuticals (NASDAQ:KERX ... - The Point Review - The Point ReviewWorth Chasing Stocks: Cellectar Biosciences Inc (NASDAQ:CLRB), Keryx Biopharmaceuticals (NASDAQ:KERX ...The Point ReviewShares of Cellectar Biosciences Inc (NASDAQ:CLRB) flew 19.11% to $3.75 at 11:54 AM EDT. The stock attained the volume of 1.84 Million shares recently versus average trading volume of 3.06 Million shares. If we take a look on its volatility, 12.57 ...and more »
06/02/16 05:05 PMStock's Earnings Analysis Report: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Cymabay Therapeutics, Inc ... - Beacon Chronicle - Beacon ChronicleStock's Earnings Analysis Report: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Cymabay Therapeutics, Inc ...Beacon ChronicleLast Trade: The Company closed its last session at $5.98 with the loss of -0.5%. The market capitalization of the company is $616.6 Million, with the average Volume of 1.7 Million. The stock currently has its 52-Week High range of $10.55 and 52-week ...and more »
06/02/16 05:05 PMKeryx Biopharmaceuticals (KERX) Is Strong On High Volume Today - TheStreet.com - TheStreet.comKeryx Biopharmaceuticals (KERX) Is Strong On High Volume TodayTheStreet.comThe average volume for Keryx Biopharmaceuticals has been 1.7 million shares per day over the past 30 days. Keryx has a market cap of $636.0 million and is part of the health care sector and drugs industry. The stock has a beta of 3.05 and a short float ...Thursday's Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn's Inc ...Smarter Analyst2 Sizzling Hot Biotechnology Stocks: Keryx Biopharmaceuticals Inc. (KERX), Cymabay Therapeutics, Inc. (CBAY)ZergwatchStock's Move to Focus: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Clovis Oncology, Inc. (NASDAQ:CLVS)Street Updatesshare market updates (press release) -HNN -Share Trading Newsall 13 news articles »
06/02/16 01:42 PMWhy Keryx Biopharmaceuticals Shouldn't Be Up Today - The devil is in the details.
06/02/16 07:40 AMTarget Price and Stock Performance Rundown for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - HNN - Target Price and Stock Performance Rundown for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)HNNDuring the latest trading session, Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares traded +1.16%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/02/16 07:40 AMBroker Watchlist: Keryx Biopharmaceuticals, Inc. (KERX) - Share Trading News - Broker Watchlist: Keryx Biopharmaceuticals, Inc. (KERX)Share Trading News03/20/2015 – Keryx Biopharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 18 price target on the stock. The share price of Keryx Biopharmaceuticals, Inc. (KERX) was down -0.50% during the last ...
06/01/16 05:12 PMBRIEF-The Baupost Group L.L.C. reports 42.53 pct stake in Keryx Biopharmaceuticals - SEC filing - * The Baupost Group, L.L.C. reports 42.53% stake in Keryx Biopharmaceuticals Inc as of May 27, 2016 - SEC FILING
05/31/16 04:59 PMStrong Sell Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 0 - Investor Newswire - Strong Sell Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 0Investor NewswireKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has a total of 6 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/31/16 08:37 AMStock's Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Advaxis, Inc. (NASDAQ:ADXS) - Street Updates - share market updates (press release)Stock's Price Moves: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Advaxis, Inc. (NASDAQ:ADXS)Street UpdatesKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) accumulated +2.63%, closing at $5.86 after floating between $5.70 and $5.86. The company has market capitalization of $620.11M. It has twelve month low of $2.80 and twelve month high of $10.80.HC Stocks Impression: Galena Biopharma Inc (NASDAQ:GALE), Keryx Biopharmaceuticals (NASDAQ:KERX)share market updates (press release)Biotech Companies To Look Out For: Keryx Biopharmaceuticals Inc. (KERX), PDL BioPharma, Inc. (PDLI)ZergwatchAfter Last Week What Do Analysts Think Of Keryx Biopharmaceuticals, Inc. (KERX)Share Trading NewsBenchmark Monitorall 5 news articles »
05/30/16 11:22 PMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS Estimate At $-0.17 - RealistInvestor.com - Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS Estimate At $-0.17RealistInvestor.comFirst Call stated that Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) can touch $8.15 in coming one year. For the next quarter, the per-share earnings target is $-0.17 and for ongoing fiscal at $-0.96. EPS target for next year is $-0.32 versus the mean ...and more »
05/30/16 11:22 PMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EBIT At $-23.397 Millions - Investor Newswire - Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EBIT At $-23.397 MillionsInvestor NewswireKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) costs of goods sold was $6.644 millions for the year ended 2016-03-31. This figure was $6.644 for the quarter ended 2016-03-31. Cost of goods sold is recorded by firm on the income statement. It is called as ...and more »
05/30/16 02:43 PMHC Stocks Impression: Galena Biopharma Inc (NASDAQ:GALE), Keryx Biopharmaceuticals (NASDAQ:KERX) - share market updates (press release) - share market updates (press release)HC Stocks Impression: Galena Biopharma Inc (NASDAQ:GALE), Keryx Biopharmaceuticals (NASDAQ:KERX)share market updates (press release)Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Friday session in green amid volatile trading. The shares closed up +0.03 points or 1.76% at $1.73 with 979,148.00 shares getting traded. Post opening the session at $1.75, the shares hit an intraday ...After Last Week What Do Analysts Think Of Keryx Biopharmaceuticals, Inc. (KERX)Share Trading Newsall 3 news articles »
05/27/16 03:35 PMKERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
05/27/16 02:46 PMTraders Focused Stocks: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Street Updates - Traders Focused Stocks: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Opexa Therapeutics, Inc. (NASDAQ:OPXA)Street UpdatesOn 5/26/2016, shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rose +0.18% in trading session and finally closed at $5.71. The company most recent volume stood at 835.8 thousand shares as compared to its average volume of 1.76 million shares.
05/26/16 07:49 PMKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Reports Yearly Sales Estimate At $451.502 - RealistInvestor.com - Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Reports Yearly Sales Estimate At $451.502RealistInvestor.comAs many as 3 analysts reported that average annual sales estimate for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) stands at $451.502 and the median is $392.51 for the period closed 4. The lowest sales forecast is $233.596 and the highest sales ...and more »
05/25/16 12:56 AMKeryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Shorted Shares Increased By 2.66% - Wall Street Hints and News - Keryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Shorted Shares Increased By 2.66%Wall Street Hints and NewsThe stock of Keryx Biopharmaceuticals Incorporated (NASDAQ:KERX) registered an increase of 2.66% in short interest. KERX's total short interest was 20.41 million shares in May as published by FINRA. Its up 2.66% from 19.89M shares, reported previously.
05/23/16 04:16 PMETF’s with exposure to Keryx Biopharmaceuticals, Inc. : May 23, 2016 -
05/23/16 02:40 PMNotable Price Swings: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , PerkinElmer, Inc. (NYSE:PKI) - Street Updates - iStreetWireNotable Price Swings: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , PerkinElmer, Inc. (NYSE:PKI)Street UpdatesOn 5/20/2016, Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) ended trading session higher at $5.74 with +3.80%. The company traded a volume of 1.14 million shares as comparison to average volume of 1.77 million shares. During the 52 –week period, ...Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Closes At $5.74Investor NewswireKeryx Biopharmaceuticals Inc. (NASDAQ:KERX) at $5.74: How much higher it can goiStreetWireall 4 news articles »
05/22/16 07:38 PMNext Weeks Broker Price Targets For Keryx Biopharmaceuticals, Inc. (KERX) - Share Trading News - Next Weeks Broker Price Targets For Keryx Biopharmaceuticals, Inc. (KERX)Share Trading News02/26/2016 – Keryx Biopharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. 02/25/2016 – Keryx Biopharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 10 price target on the stock.Is it Time to Cash in Profits on Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)Franklin Independentall 4 news articles »
05/20/16 07:48 PMBuy Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 1 - RealistInvestor.com - Buy Calls Count For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At 1RealistInvestor.comZacks line of rating gives scores to firms on a basic 1-5 scale. As per this rating line, a score close to the lower band of 1-2 indicates a Buy, 3 rating calls for Hold while 4 or 5 rating denotes Sell. Most of the research firms have their self ...and more »
05/15/16 02:53 PMAfter Last Week What Do Analysts Think Of Keryx Biopharmaceuticals, Inc. (KERX) - Share Trading News - After Last Week What Do Analysts Think Of Keryx Biopharmaceuticals, Inc. (KERX)Share Trading News03/20/2015 – Keryx Biopharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 18 price target on the stock. The share price of Keryx Biopharmaceuticals, Inc. (KERX) was up +3.38% during the last ...Analyst Price Target Updates: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), C.R. Bard, Inc. (NYSE:BCR)WsNews 4investorsall 2 news articles »
05/12/16 02:52 PMEarnings per Share Report: Keryx Biopharmaceuticals (NASDAQ:KERX) - News Oracle - News OracleEarnings per Share Report: Keryx Biopharmaceuticals (NASDAQ:KERX)News OracleLast Trade: The Company fell -3.14% and finished at $5.25. The daily volume was measured at 727,600.00 shares. The 52-week high of the share price is $11.12 and the 52-week low is $2.80. The company has a market cap of $550.48 million. Its latest ...and more »
05/11/16 02:52 PMEarnings Report: Keryx Biopharmaceuticals (KERX) - News Oracle - Earnings Report: Keryx Biopharmaceuticals (KERX)News OracleLast Trade: The Company fell -0.91% and finished at $5.42. The daily volume was measured at 1.04 million shares. The 52-week high of the share price is $11.12 and the 52-week low is $2.80. The company has a market cap of $565.04 million. Its latest ...and more »
05/07/16 01:05 AMEarnings Outlook on Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - B.O.D.Y Confidential - Earnings Outlook on Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)'s next earnings release which is expected to be posted on or around 2016-08-03. Sell-side research firms on Wall Street are expecting that the company will post ...and more »
05/06/16 07:58 PMKeryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Sellers Covered 12.2% of Their Shorts - B.O.D.Y Confidential - Keryx Biopharmaceuticals Incorporated (NASDAQ:KERX) Sellers Covered 12.2% of Their ShortsB.O.D.Y ConfidentialThe stock of Keryx Biopharmaceuticals Incorporated (NASDAQ:KERX) registered a decrease of 12.2% in short interest. KERX's total short interest was 19.89 million shares in May as published by FINRA. Its down 12.2% from 22.65 million shares, reported ...and more »
About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KERX
  • CUSIP: 49251510
Key Metrics:
  • Previous Close: $6.62
  • 50 Day Moving Average: $5.92
  • 200 Day Moving Average: $4.82
  • P/E Ratio: N/A
  • P/E Growth: -0.06
  • Market Cap: $700.53M
  • Current Quarter EPS Consensus Estimate: $-0.96 EPS
Additional Links:
Keryx Biopharmaceuticals (NASDAQ:KERX) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha